27562951|t|Therapeutic applications of CRISPR RNA-guided genome editing
27562951|a|The rapid development of programmable nuclease -based genome editing technologies has enabled targeted gene disruption and correction both in vitro and in vivo This revolution opens up the possibility of precise genome editing at target genomic sites to modulate gene function in animals and plants. Among several programmable nucleases, the type II clustered regularly interspaced short palindromic repeats (CRISPR)- CRISPR-associated nuclease 9 (Cas9) system has progressed remarkably in recent years, leading to its widespread use in research, medicine and biotechnology. In particular, CRISPR-Cas9 shows highly efficient gene editing activity for therapeutic purposes in systems ranging from patient stem cells to animal models. However, the development of therapeutic approaches and delivery methods remains a great challenge for biomedical applications. Herein, we review therapeutic applications that use the CRISPR-Cas9 system and discuss the possibilities and challenges ahead.
27562951	0	24	Therapeutic applications	T169	C0039798
27562951	28	34	CRISPR	T114	C3658200
27562951	35	45	RNA-guided	T114,T123	C0082774
27562951	46	60	genome editing	T063	C4279981
27562951	86	107	programmable nuclease	T116,T126	C0597094
27562951	115	129	genome editing	T063	C4279981
27562951	130	142	technologies	T090	C0039421
27562951	155	163	targeted	T169	C1521840
27562951	164	168	gene	T028	C0017337
27562951	169	179	disruption	T169	C0332453
27562951	184	194	correction	T061,T063	C1720855
27562951	200	208	in vitro	T080	C1533691
27562951	213	220	in vivo	T082	C1515655
27562951	273	287	genome editing	T063	C4279981
27562951	291	297	target	T169	C1521840
27562951	298	311	genomic sites	T082	C1880951
27562951	324	337	gene function	T045	C0314627
27562951	341	348	animals	T008	C0003062
27562951	353	359	plants	T002	C0032098
27562951	375	397	programmable nucleases	T116,T126	C0597094
27562951	403	468	type II clustered regularly interspaced short palindromic repeats	T114	C3658200
27562951	470	476	CRISPR	T114	C3658200
27562951	479	521	CRISPR-associated nuclease 9 (Cas9) system	T044	C3658355
27562951	598	606	research	T062	C0035168
27562951	608	616	medicine	T091	C0025118
27562951	621	634	biotechnology	T091	C0005574
27562951	651	662	CRISPR-Cas9	T044	C3658355
27562951	686	698	gene editing	T063	C4279981
27562951	712	732	therapeutic purposes	T169	C0039798
27562951	757	764	patient	T101	C0030705
27562951	765	775	stem cells	T025	C0038250
27562951	779	792	animal models	T008	C0599779
27562951	822	844	therapeutic approaches	T169	C0039798
27562951	849	865	delivery methods	T061	C0565867
27562951	896	906	biomedical	T091	C1879848
27562951	907	919	applications	T169	C0039798
27562951	939	963	therapeutic applications	T169	C0039798
27562951	977	995	CRISPR-Cas9 system	T044	C3658355